European Echinococcosis Registry: Human Alveolar Echinococcosis, Europe, 1982–2000 by Kern, Petra et al.
Emerging Infectious Diseases • Vol. 9, No. 3, March 2003 343
RESEARCH
Surveillance for alveolar echinococcosis in central Europe
was initiated in 1998. On a voluntary basis, 559 patients were
reported to the registry. Most cases originated from rural com-
munities in regions from eastern France to western Austria; sin-
gle cases were reported far away from the disease-“endemic”
zone throughout central Europe. Of 210 patients, 61.4% were
involved in vocational or part-time farming, gardening, forestry,
or hunting. Patients were diagnosed at a mean age of 52.5
years; 78% had symptoms. Alveolar echinococcosis primarily
manifested as a liver disease. Of the 559 patients, 190 (34%)
were already affected by spread of the parasitic larval tissue. Of
408 (73%) patients alive in 2000, 4.9% were cured. The increas-
ing prevalence of Echinococcus multilocularis in foxes in rural
and urban areas of central Europe and the occurrence of cases
outside the alveolar echinococcosis–endemic regions suggest
that this disease deserves increased attention.
H
uman alveolar echinococcosis, caused by the metacestode
of the fox tapeworm Echinococcus multilocularis, is con-
sidered to be the most pathogenic zoonosis in temperate and
arctic regions of the Northern Hemisphere. Transmission to
humans occurs when eggs of the tapeworm, excreted by the
final hosts (usually foxes), are accidentally ingested. The
larva’s primary target organ is the liver, where it proliferates
slowly, but the larva also spreads into extrahepatic structures
and even metastasizes to distant organs. In earlier untreated
cohorts, the fatality rate exceeded 90% within 10 years (1). The
introduction of benzimidazoles for alveolar echinococcosis
treatment in 1976 has considerably improved the prognosis
(2,3). Long-term follow-up of 117 patients showed that the 5-
year actuarial survival rate increased to 88% with this
improved management (4). As chemotherapy is parasitostatic
only, long-term administration is mandatory for most patients
(5,6). Radical surgical excision, the only curative treatment, is
feasible in a few select cases (7). 
In Europe, previous assessments of human cases did not
cover all alveolar echinococcosis–endemic areas at comparable
periods. In Switzerland, where laboratory-diagnosed alveolar
echinococcosis was a reportable disease until 1997, the annual
incidence ranged from 7.2 to 10.4 (0.10–0.18/100,000) and did
not markedly vary during a 36-year period (8). In Austria, an
average incidence of 2.5 cases per year corresponded to an inci-
dence of 0.034/100,000 from 1985 to 1999 (9). These low num-
bers of human infections throughout a whole country failed to
alarm public health authorities. However, two findings are
beginning to attract more attention: 1) high annual incidence
rates occurring regularly in particular regions, e.g., the Swiss
Jura (0.74/100,000) (10); and 2) a presumed range extension of
the parasite in its sylvatic life cycle.
In Europe, the Red Fox (Vulpes vulpes) is the most impor-
tant final host for E. multilocularis. Reviews based on the data
collected during the past decade have shown that the natural
range of the parasite extends farther to the east and north in
Europe than previously thought (11,12). Defined rural areas
have been monitored regularly for many years, and increasing
parasite prevalence rates in foxes have been recorded (13).
Clusters of high endemicity (60% to 75%) have been found
(14). Increasing fox populations have been reported from sev-
eral European countries (13). Foxes migrating to urban areas
are also causing concerns: E. multilocularis prevalence rates of
20% and 48% have been recorded in Stuttgart, Germany (11),
and Zürich, Switzerland, respectively (15). 
Knowledge of the parasite’s range and prevalence in ani-
mal hosts has thus grown during recent years. However, com-
prehensive assessments of human alveolar echinococcosis cov-
ering the known risk areas across European countries have not
been performed. To provide baseline data for future risk calcu-
lations and to establish a prospective case retrieval, the
European Echinococcosis Registry (EurEchinoReg) created a
network of reporting centers in 11 countries of western and
central Europe and Turkey. This report provides the status of
reporting, origin, and clinical and epidemiologic data of such
patients reported to the registry up to the year 2000.
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Case Retrieval
Case detection and data collection have been organized by
each participating country according to the existing infrastruc-
ture of the national health systems and the availability of data
sources. In the EurEchinoReg, experts from universities
(research units and hospitals) and public health authorities
cooperate in eight countries of the European Union (Austria,
Belgium, France, Germany, Greece, Great Britain, Italy, and the
Netherlands), and in Switzerland, Poland, the Czech Republic,
and Turkey. Patient data are stripped of identifiers and sent to
two subregistries (the University of Franche-Comté, Besançon,
France and the University of Ulm, Ulm, Germany), where they
are controlled and approved for electronic recording. 
Case Definition and Period of Inclusion
Diagnosis of alveolar echinococcosis is confirmed by 1)
positive histopathology, if available and/or 2) typical liver
lesion morphology identified by imaging techniques (ultra-
sound scan, computed tomography, and magnetic resonance
imaging) with or without the detection of serum antibodies
(serology). Positive serologic results without suggestive imag-
ing findings or positive histopathology does not qualify for a
case definition. 
The period of inclusion began in 1982, when benzimida-
zoles, ultrasound, and other imaging techniques (which facili-
tated diagnosis, treatment, and follow-up) were introduced. The
registry includes all confirmed new cases from January 1982 to
December 2000, as well as cases with a diagnosis from earlier
periods, provided the patients were alive in 1982 and their diag-
nosis was confirmed with the appropriate techniques in 1982 or
later.
Case Report Form and Completeness of Registration
Patients were asked to allow their nominal registration at
their national center, in conformity with the national legislation
for data privacy to avoid double registration and to facilitate
follow-up. Two questionnaires are used: an epidemiologic part
to be answered by the patient and a clinical part to be complet-
ed by the reporting physician. In addition to demographic base-
line data, we gathered information on year of diagnosis, disease
manifestation at the time of the diagnosis, co-existing condi-
tions; diagnostic and therapeutic measures, year of death, pre-
sumed cause of death, places of residence, and occupation in
agriculture, forestry, and gardening. 
Data files from the study groups in Austria, France,
Germany, and Switzerland were the basis for the European
patient registry; additional case files were collected by active
case finding and with the help of physicians from hospitals and
private practices. Completeness of registration can be assumed:
1) in France, since access to patient files is facilitated by a cen-
tralized distribution of albendazole by a few university hospi-
tals; 2) in Austria, since laboratory diagnosis is made in a sin-
gle institution; and 3) in Switzerland, where alveolar
echinococcosis was a reportable disease until 1997; case
reports are thus complete from the 1970s until 1997.
Underreporting is likely in Germany, where reporting relies
entirely on the cooperation of family physicians and clinicians.
In Belgium, Greece, and Poland, alveolar echinococcosis
seems to be newly emerging, and cases are discussed in the
medical community; the cases reported to the registry should
reflect the true prevalence in these countries. 
Data Analysis
The combined data sets for all European patients are kept
in an Access database (Microsoft Corp., Redmond, WA).
Descriptive analyses were made with SAS software V8 (SAS
Institute, Inc., Cary, NC). The regional distribution of alveolar
echinococcosis cases was mapped with the software package
RegioGraph 5.1 (GfK MACON AG, Waghäusel, Germany). 
Results
Epidemiology
The total number of verified alveolar echinococcosis cases
reported to the registry was 559; 42.0% were diagnosed in
France, 23.6% in Germany, and 21.1% in Switzerland (Table
1). Fifteen patients acquired the infection outside their report-
ing country, 7 of these cases originated from one of the neigh-
boring countries, 8 were of non-European origin. 
During the reporting period, the number of new cases var-
ied from year to year. From 1981 to 2000, a peak incidence of
36 was noted in 1988; aside from this 1 year, reports ranged
from 15 to 27 patients. A total of 258 patients were male
(46.2%) and 301 female (53.8%) (gender ratio 1:1.2). The
median age at first diagnosis was 56 (mean 52.5, range 5–86
years) and was almost equal in men and women (Figure 1). The
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Table 1. Number of patients with alveolar echinococcosis, Europe 
Reporting country 
Yr of first diagnosis  Austria  Belgium  France  Germany  Great Britain  Netherlands  Switzerland  Poland  Greece  Total
a 
Until 1980  8  0  23  30  0  0  43  0  0  104 
1981–1985  12  0  60  11  0  0  29  0  0  112 
1986–1990  11  0  80  17  0  0  17  2  0  127 
1991–1995  13  0  40  26  0  0  16  6  0  101 
1996–2000  10  3  32  48  1  1  13  6  1  115 
Total no. of patients
b  54 (1)  3  235  132(6)  1 (1)  1 (1)  118 (6)  14  1  559 
aStatus of notification to the European Echinococcosis Registry as of August 2001. 
bIncludes 15 non-autochthonous cases (in parentheses); 7 of them originated from neighboring countries, 3 from Turkey, 3 from the Newly Independent States, 1 from Kazakhstan, 
and 1 from Afghanistan. proportion of patients <20 years old was 2.1% (12/559); 88
(15.7%) were >69 years of age. For four patients (0.7%), the
year of birth was missing. Three of the four children in this case
series, ages 5 and 7 when diagnosed, had severe organ damage;
two were immunocompromised. 
Information on potential risk factors was available for 210
(37.6%) patients from Austria, Germany, Greece, and France
(Table 2), including 97 men and 113 women. Of these, 21.9%
were farmers. In addition, of all the patients engaged in other
professions (including housewives and students), 46.2% regu-
larly farmed, gardened, or performed related activities as a pas-
time. Of all pensioners and unemployed patients, 62.2% also
gardened, farmed, or the like. Most patients (70.5%) owned or
formerly kept dogs and cats. Among these pet owners, 105 per-
sons also actively farmed or gardened. Only 15 patients (7.1%)
did not farm, garden, or own pets. 
Geographic Distribution
Figure 2 gives the residence at the time of diagnosis or at
the time of the last medical report for 532 alveolar echinococ-
cosis patients; cases were autochthonous from the countries
represented on the map. The patient from Greece lived in
Macedonia. Data were unavailable for 18 patients. 
Most residences were clustered in defined regions: central
France, French Jura and Savoy, Swiss Jura and northeastern
Switzerland, southern Germany, and western Austria. Single
cases were identified in Belgium, the northern regions of
France, Germany, and Poland, and northeastern Austria. For the
period 1980–1999, a total of 201 cases were reported from
Turkey; all originated from the Asian part of the country, most-
ly from eastern Anatolia. However, the aggregated data
(reviewed by Altintas et al. [16]) could not be combined with
the detailed datasets from western and central Europe. No
autochthonous cases were reported from the Netherlands, the
Czech Republic, the Slovak Republic, Italy, or the U.K.
Clinical Data
Table 3 lists the main diagnostic procedures, conducted
within a time span of 6 months after initial examination, which
led to the diagnosis of alveolar echinococcosis. A total of
53.5% of diagnoses were definitely confirmed by positive
histopathology; 38.5% were ascertained by imaging techniques
combined with serology, or imaging alone, when obtaining tis-
sue specimens for analysis was not possible. Information on
diagnostic procedures was missing for 7.7% of the patients. 
In 397 (71.0%) of the 559 cases, the diagnosis was made
after the patients reported symptoms; 66 (11.8%) cases were
disclosed by chance in the course of a general medical check-
up or an examination related to other diseases; and 18 (3.2%)
cases were found during studies that screened for alveolar
echinococcosis. Data on these circumstances were not avail-
able for 78 (14%) of 559 patients.
The primary infection site was the liver for almost all
patients, and primary extrahepatic lesions without any involve-
ment of the liver were diagnosed in 13 patients (Table 4). At
first diagnosis, the liver was the only affected organ for 351
(62.8%) of 559 patients. Damage to the liver included single or
multiple lesions in one or more segments of one or both liver
lobes, the hilus region, the intrahepatic portal vein, hepatic
vein, or bile duct. Approximately one third (34%) of the
patients (190/559) were already affected by a spread of the lar-
val tissue either in continuum into neighboring organs, by the
formation of distant metastases, or both. Specific details of
organ damage were available for 178 of 190 patients. The
organs most frequently affected by continuous growth were the
diaphragm (59 patients), kidneys or adrenal glands (26
patients), and lungs and pleura (15 patients). Metastases
occurred mainly in the lungs (39 patients), brain (17 patients),
and spleen (10 patients).
At the time of reporting, 267 (47.8%) of the 559 patients
had undergone surgery and received benzimidazoles; 200
(35.8%) were treated with these drugs alone, and 48 (8.6%) by
surgery alone. A total of 29 patients (5.2%) underwent liver
transplantation. Twenty-two patients (3.9%) had not received
any treatment during the time between diagnosis and notifica-
tion; another 13 (2.3%) had apparently had inadequate treat-
ment. For 9 patients (1.6%) the chosen treatment options were
not specified. 
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Figure 1. Patients with alveolar echinococcosis reported to the
European Registry. Age at first diagnosis by gender (N=555, year of
birth missing for 4 patients).
Table 2. Possible exposure risks assessed for 210 patients with alveolar echinococcosis 
Activity in agriculture, gardening, forestry, hunting  Ownership of dogs, cats, or both 
Occupation  N (%)  Yes  No  Missing  Yes  No  Missing 
Farmers  46 (21.9)  46  0  0  39  2  5 
Nonfarmers
a  119 (56.7)  55  56  8  80  13  26 
Occupation not specified, including 
unemployed and pensioners 
45 (21.4)  28  13  4  29  6  10 
Total   210 (100.0)  129  69  12  148  21  41 
aFor example, tailors, hairdressers, cooks, nurses, drivers, teachers, students, and housewives. By December 2000, 73.0% of the patients were alive,
21.3% had died, and 5.7% were lost to follow-up (Table 5). Of
the patients still alive, disease activity was assessed at their last
clinical examination as follows: cured (20 patients, 4.9%); sta-
ble or regressive (226 patients, 55.4%); or progression, seque-
lae, or complications caused by larval growth or occurring after
intervention (43 patients, 10.5%). An assessment was not pro-
vided for 119 patients (29.2%); many of them had been diag-
nosed recently, and treatment had just begun. Death was defi-
nitely associated with alveolar echinococcosis in 13 (10.9%) of
the 119 cases; in 15 cases (12.6%) death was probably related
to this disease. In 20 patients (16.8%), death was definitely
independent of the diagnosis of alveolar echinococcosis. No
assessment was available for 71 patients (59.7%). 
Discussion
In 1998, the EurEchinoReg network initiated the assessment
of human alveolar echinococcosis across European borders. The
reasons for promoting concerted efforts to survey a disease
thought to be rare in Europe were as follows: 1) the disease is one
of the most aggressive chronic liver diseases, 2) comprehensive
assessments of human cases covering all known risk areas were
not available, 3) the routes of transmission to humans are still
hypothetical, and 4) the range of the parasite in its life cycle
seems to have extended, posing threats in previously unaffected
areas. 
The assessment included patients from former clinical
studies and cases identified by active case finding. Nine
European countries reported on 559 patients; cases were
autochthonous from seven of these countries. The median num-
bers per year did not vary during two decades (24 in 1980s; 22
in 1990s). Underreporting from previous years was responsible
for a seemingly increasing incidence in Germany; underreport-
ing since 1998 explains a decline in Switzerland. High numbers
in France in the mid-1980s could be an effect of mass screen-
ings performed at that time in alveolar echinococcosis–endem-
ic areas, which may have raised awareness of the disease. In the
past, the number of verified and published cases from Europe
(Austria, France, Germany, and Switzerland) amounted to 844
cases or 10.6 cases per year (published between 1900 and
1980) (17). The patient numbers from our report reflect what is
probably an optimal detection rate owing to improved technol-
ogy. Thus, low but constant incidence is characteristic of the
occurrence of human alveolar echinococcosis in Europe today.
In this parasitic infection, a long incubation period seems
to precede diagnosis. Albeit difficult to prove, the initial
asymptomatic period is assumed to last 5–15 years (1). (This
conclusion is derived from the small proportion of patients <20
years old at diagnosis [2.1% in this report]). Determining the
time and place of infection is difficult. Assuming that in
humans, who are unsuitable hosts for E. multilocularis, repeat-
ed or long-term exposure is required before an infection
becomes established, these conditions are more likely to be met
by outdoor activities close to the place of residence than by
travels to alveolar echinococcosis–endemic areas. We therefore
assume that for most cases, the place of residence is most like-
ly the area of infection. A complete documentation of all the
places where the patients had lived during their lives was avail-
able for approximately 30%. Mobility of this patient subgroup
was low, in conjunction with long-term farming. 
The distribution of alveolar echinococcosis in Europe
shows a core area with a high density of cases and border areas
with clusters of a few patients or single cases. The core area
covers large parts of the classic alveolar echinococcosis–
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Figure 2. Regional distribution of autochthonous alveolar echinococco-
sis in Europe, from 532 diagnoses ascertained from 1982 to 2000. Dots
represent place of residence (at time of diagnosis or last medical
record) of 1–5 patients. In Austria, Belgium, Germany, and Poland,
administrative units for locating patients are the municipality; in France
and Switzerland, dots are placed at random in larger units
(“Arrondissement” for France, “Kanton” for Switzerland). Source:
European Echinococcosis Registry, Ulm, Besançon, 2001. Used with
permission. 
Table 3. Diagnostic procedures to ascertain the diagnosis of alveolar 
echinococcosis
a 
Histopathology
b  Imaging
c  Serology
d  No. of patients (%) 
+  +  +  176 (31.5) 
+  +  –  48 (8.6) 
+  –  +  19 (3.4) 
+  –  –  56 (10.0) 
Subtotal  299 (53.5) 
-  +  +  192 (34.3) 
-  +  -  25 (4.5) 
Subtotal  217 (38.8) 
Data not available  43 (7.7) 
Total  559 (100.0) 
aAll documented techniques, applied during 6 months after initial examination. +, 
positive result in the respective tests/examinations; –, negative result, tests/examinations 
not done, or data not available. 
bExamination of liver tissue samples carried out on material removed by surgery, 
diagnostic laparoscopy, or, in rare instances, by fine needle biopsy. 
cComprised one or several examinations, i.e., ultrasound, computed tomography (CT), or 
magnetic resonance imagry (MRI) of the abdomen. In some cases, X-ray, CT, or MRI 
were available on brain, chest, or other organs. 
dIncluded screening methods using different crude antigen preparations in indirect 
hemagglutination or enzyme-linked immunosorbent assays (ELISA). In addition, 
purified and recombinant antigen preparations such as Em2+, Em10 or Em18 were used 
in ELISA, Western blot, or both. endemic regions in Austria, France, Germany, and Switzerland,
including those where the index cases from each of these coun-
tries have been identified since 1855 (17). In these areas, recent
screening studies have detected not only a small number of
manifest diseases but also self-cured infections (aborted
lesions, first described by Rausch et al. [18]), and seropositivi-
ty rates of up to 2% (14,19,20). Fifteen persons with aborted
hepatic lesions (lesions with characteristic calcification) and
positive serologic results were reported to the registry but were
excluded from this analysis, since a definite diagnosis based on
histopathologic or molecular findings had not been provided.
Together with a persistent E. multilocularis seroprevalence,
such reports point to a manifest infection pressure in the core
area.
In the core area, a consistently high prevalence of E. mul-
tilocularis in foxes has been reported, e.g., >50% in southwest-
ern Germany (11), 44% in western Bavaria (21), 65% in east-
ern France (13), and 35% in western Austria (9). In the border
area with less frequent and more dispersed human cases, fewer
investigations have been undertaken to establish parasite preva-
lence, and the figures determined rely on low numbers of
examined foxes. The prevalence was generally low, e.g., 13%
in northern Germany (11), 8% to 21% in eastern Bavaria (21),
and 10% in eastern Austria (9). In Belgium, the first three
patients with autochthonous infections lived in areas with low
parasite prevalence (final report to the European Commission,
Directorate General V (EurEchinoReg, unpub. data, 1999). No
prevalence data are available for northern France. In Poland,
parasite prevalence was initially investigated in 1994. All reg-
istered patients live in the northeastern districts with the high-
est prevalence (20% and 36%) (22). In Greece, sporadic cases
had been reported previously (23). 
Whether low parasite prevalence exerts an infection pres-
sure relevant for transmission to humans remains questionable.
Recent investigations have shown that foci of high prevalence
can persist, even for long periods, in regions where the overall
infection rates in foxes are low (e.g., foci of 25% in areas with
5% in eastern Germany) (24). Similar foci may exist in other
regions but are undetected to date. Thus, human infection can
probably occur in regions with low overall parasite prevalence,
and we regard case reports from areas remote from the core
area as strong hints of new areas at risk. Therefore, threshold
findings at diagnosis should not be rated as incompatible with
the disease when the patient lived in an area where human alve-
olar echinococcosis was unknown before. According to Eckert
et al. (12), all regions with a proven occurrence of E. multiloc-
ularis in Red Foxes indicate a “potential risk area,” irrespective
of the magnitude of prevalence rates. This view is the basis for
the current concept of a continuous distribution of the parasite
in Europe from central France to Poland. Future studies should,
therefore, address the redefinition of risk areas for alveolar
echinococcosis and the population at risk. 
Transmission of the parasite to humans occurs rarely, and
individual risk factors for human disease are not well under-
stood. In Europe, only one case-control study has been pub-
lished; this study included 21 patients and 84 controls from
Austria (25). A high association of the disease was found with
cat ownership and hunting, but because of the low case number
the study was of limited power. Farming did not seem to have
an impact on infection risk. In China, a population-based study
showed that farming was the most important risk factor (26). In
Alaska, dog ownership was found to be associated with the dis-
ease (19 patients, 38 controls) (27). None of these studies found
an association of the disease with a history of picking and eat-
ing wild berries and mushrooms or raw produce from unfenced
gardens. Also, neither fox hunters in China (26) nor trappers in
South Dakota, United States, are affected by the disease (28).
The records of 210 patients from the European registry data
show that 21.9% were farmers; another 39.5% were engaged in
farming, gardening, hunting, or working in forestry as a pas-
time; 70.5% of all patients kept dogs or cats. These data point
to a high frequency of putative exposure, but the lack of a com-
parison group does not allow an evaluation of the risk potential
of these activities. These activities may be characteristic of
most people in rural communities in Europe. For Europe, the
questions of how risk behavior can be defined and how expo-
sure can best be prevented are, therefore, still unanswered. 
Within the last 20 years, major improvements have been
made in the diagnosis and treatment of alveolar echinococco-
sis. Definite diagnosis by histopathology was available in
53.3% of this case series; the remaining cases were ascertained
by imaging with or without specific serology. At diagnosis,
34% of the patients were already affected by advanced larval
growth; when the parasitic tissue does not affect important
organs or vessels, it may go unnoticed for prolonged periods.
This fact may also explain a diagnosis late in a patient’s life. In
Europe, the mean age at diagnosis was slightly higher than in
non-Caucasian populations, i.e., in Hokkaido, Japan (48.7
years) (29), or in China (35.7 years) (30).
Immunodeficiencies, e.g. HIV infection (31) or immuno-
suppressive therapy after liver transplantation (32), may possi-
bly accelerate the manifestation of alveolar echinococcosis.
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Table 4. Location of the primary lesions at first diagnosis in alveolar 
echinococcosis 
Primary infection site  No. of patients 
Liver  541 (96.8%) 
Spleen, peritoneum, lung, vertebra, brain, kidneys, heart  13 (2.3%) 
Data not available  5 (0.9%) 
Total  559 
Table 5. Vital status of patients with alveolar echinococcosis, as of December 
2000 
No. of patients 
Yr of first 
diagnosis  Alive 
Lost to 
follow-up  Deceased 
Interval between 
diagnosis and  
death (yrs) 
Until 1980  63  4  37  4–29 
1981–1985  73  11  28  <1–14 
1986–1990  84  9  34  <1–10 
1991–1995  85  6  10  1–4 
1996–2000  103  2  10  <1–1 
Total  408  32  119   Chemotherapy with benzimidazoles was the only treatment for
one third of the registered patients; complete cure after surgery
and adjuvant chemotherapy was achieved in only 4.9%. For
most patients, stability can be achieved with long-term
chemotherapy, with or without surgery or interventional radiol-
ogy, but the disorder remains chronic.
This report is the first collection of data on human alveo-
lar echinococcosis in Europe. Our study confirms that an infec-
tion with this parasite is still dangerous. Alow annual incidence
persists in the previously known foci. However, case reports
from regions remote from the core area indicate that the disease
is spreading. We therefore recommend that the occurrence of
this potentially reemerging zoonosis should be continuously
monitored in western and central Europe. 
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